Once-weekly exenatide vs daily sitagliptin or pioglitazone
Links shared publicly online about this topic.
- 1,982total visits
Once-weekly exenatide vs daily sitagliptin or pioglitazone
The investigational glucagonlike peptide-1 receptor agonist exenatide lowers hemoglobin A1C levels to a greater extent; more patients with type 2 diabetes reached A1C targets.
View full resource at theheart.org
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Actos, Byetta, Januvia
Most Recently Shared on June 9, 2009 at 6:28 pm By:
heartwire: Once-weekly exenatide achieves better glycemic control than daily sitagliptin or pioglitazone http://bit.ly/10diDq
Exenatide beats daily oral drugs, insulin, for lowering A<sub>1c</sub>
theheart.org — “Once-weekly exenatide was better at lowering glycosylated hemoglobin levels in patients with type2 diabetes in two randomized trials that pitted it against sitagliptin, pioglitazone, and insulin glargine.” View full resource at theheart.org
Most Recently Shared on June 28, 2010 at 11:03 pm By:
DURATION-2 and -3: Once-weekly exenatide lowers A1c more than daily oral antidiabetics or insulin glargine: Once-w... http://bit.ly/cPJW7L
Advertisement
